Cargando…

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond

Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog p...

Descripción completa

Detalles Bibliográficos
Autor principal: Cowey, C. Lance
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680638/
https://www.ncbi.nlm.nih.gov/pubmed/23888252
http://dx.doi.org/10.1007/s13555-013-0019-9
_version_ 1782273147438891008
author Cowey, C. Lance
author_facet Cowey, C. Lance
author_sort Cowey, C. Lance
collection PubMed
description Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a treatment target. Several agents that inhibit the Hedgehog pathway have reached clinical studies and one drug, vismodegib, has recently been US Food and Drug Administration (FDA) approved based on clinical activity and tolerability in patients with advanced basal-cell carcinoma. This review will describe the clinical development of vismodegib, as well as the proper application of the drug in clinical practice. Other important clinical questions, such as mechanisms of resistance to vismodegib and the role of other Hedgehog pathway inhibitors currently in development will also be discussed.
format Online
Article
Text
id pubmed-3680638
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-36806382013-06-13 Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond Cowey, C. Lance Dermatol Ther (Heidelb) Review Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a treatment target. Several agents that inhibit the Hedgehog pathway have reached clinical studies and one drug, vismodegib, has recently been US Food and Drug Administration (FDA) approved based on clinical activity and tolerability in patients with advanced basal-cell carcinoma. This review will describe the clinical development of vismodegib, as well as the proper application of the drug in clinical practice. Other important clinical questions, such as mechanisms of resistance to vismodegib and the role of other Hedgehog pathway inhibitors currently in development will also be discussed. Springer Healthcare 2013-03-02 /pmc/articles/PMC3680638/ /pubmed/23888252 http://dx.doi.org/10.1007/s13555-013-0019-9 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review
Cowey, C. Lance
Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
title Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
title_full Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
title_fullStr Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
title_full_unstemmed Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
title_short Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
title_sort targeted therapy for advanced basal-cell carcinoma: vismodegib and beyond
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680638/
https://www.ncbi.nlm.nih.gov/pubmed/23888252
http://dx.doi.org/10.1007/s13555-013-0019-9
work_keys_str_mv AT coweyclance targetedtherapyforadvancedbasalcellcarcinomavismodegibandbeyond